Hype or Help? Obesity Drug Considerations for Employers
… established cardiovascular disease. Then, the CMS (Centers for Medicare and Medicaid Services) announced that health plans under Medicare Part D could cover Wegovy when deemed medically necessary. These developments underscore the growing importance of GLP-1 medications in healthcare management. While the cardiovascular and weight loss data emphasize the potential benefits of GLP-1 medications, the financial impact – exceeding $10,000 per patient annually – has made coverage decisions challenging for employers. Additionally, clinical trial data shows that continuous, chronic use is required to maintain weight loss. In people who discontinued therapy, two-thirds of their lost weight was regained after …
https://www.epicbrokers.com/insights/weight-loss-drug-glp1-employer-considerations/